Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2010 Financial Results and Highlights
Date:11/8/2010

e nine months ended September 30, 2010, Anadys reported a net loss of $13.9 million, compared to $23.0 million for the same period last year.  Basic and diluted net loss per common share was $0.35 for the nine months ended September 30, 2010 compared to $0.71 for the same period last year.Recent Development Program Highlights
  • ANA598 to Advance into Phase IIb.  In October, Anadys announced plans to conduct a Phase IIb study of ANA598 in combination with Pegasys® (peginterferon alfa-2a) and Copegus® (ribavirin, USP) (a current standard of care, or SOC) for the treatment of chronic hepatitis C.  In the planned study, which is on track to commence early in the first quarter of 2011, approximately 200 chronically infected hepatitis C patients are expected to receive ANA598 200 mg bid in combination with SOC, while approximately 66 are to receive placebo and SOC.  Enrollment is expected to include approximately equal numbers of treatment-naïve patients and treatment-experienced patients who have failed a prior course of SOC, including difficult to treat prior null-responders.  Treatment duration for naïve patients will be response-guided, while treatment-experienced patients are to receive all three agents for 48 weeks.  On-treatment response and safety data through 24 weeks is expected in the second half of 2011. Anadys is currently finalizing discussions with the U.S. Food and Drug Administration (FDA) regarding details of the trial design, and plans to conduct the study at a number of sites within and outside the United States.  


  • ANA598 Data at AASLD.  On October 31, 2010, data from the ongoing Phase IIa trial of ANA598 in combination with SOC were presented in an oral presentation at the 61st Annual Meeting of the American Association for the Study of Liver Disease (AASLD).  The presented data showed that ANA598 added to SOC
    '/>"/>


  • SOURCE Anadys Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
    2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
    3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
    4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
    5. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
    6. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
    7. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
    8. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
    9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
    10. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
    11. Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/3/2015)... JACKSONVILLE, Fla. , March 3, 2015 /PRNewswire/ ... is pleased to announce the hiring of ... Sales to lead business development efforts and build ... years of experience in software development, sales, and ... of enterprise software applications. iTraycer is a comprehensive ...
    (Date:3/3/2015)... LOUISVILLE, Ky. , March 3, 2015 ... Louisville,s greatest leaders in aesthetics. In ... successful Brownsboro Plastic and Hand Surgery practice, Dr. Cummins ... Louisville Tattoo Removal clinic . Dr. Cummins performs ... "I founded Louisville Tattoo Removal in order ...
    (Date:3/3/2015)... March 3, 2015   ... 240 patients respectively Publications in peer reviewed ... Clinical Gastroenterology highlight diagnostic value of confocal laser ... China and across Asia ... (Euronext: MKEA, FR0010609263), inventor of Cellvizio®, the multidisciplinary confocal ...
    Breaking Medicine Technology:Medical Tracking Solutions, Inc. Hires New SVP, Sales 2Surgeon Owned And Operated Louisville Tattoo Removal Offers Astanza Duality Laser Treatments 2Two New Publications From Leading Team in China Present Data From Large Clinical Trials Highlighting Advantages of Cellvizio in Diagnosis of Gastric and Esophageal Cancers 2Two New Publications From Leading Team in China Present Data From Large Clinical Trials Highlighting Advantages of Cellvizio in Diagnosis of Gastric and Esophageal Cancers 3Two New Publications From Leading Team in China Present Data From Large Clinical Trials Highlighting Advantages of Cellvizio in Diagnosis of Gastric and Esophageal Cancers 4
    ... from a pivotal trial suggests that ofatumumab has activity ... , , , ... Genmab A/S (OMX: GEN) announced today positive results from ... in the treatment of refractory chronic lymphocytic leukemia (CLL). ...
    ... HUNTINGTON BEACH, California and AMSTERDAM, December 8 ,Agendia, ... announced that,leading Agendia and the Netherlands Cancer Institute ... 2008 San Antonio Breast Cancer Symposium,(SABCS) and Agendia ... in Individualized Breast Cancer Therapy symposium. The San ...
    Cached Medicine Technology:Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 2Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 3Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 4Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 5Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 6Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 7Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 8Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 9Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium 2Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium 3Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium 4
    (Date:3/3/2015)... 2015 -- vRad ( Virtual Radiologic ), the nation’s ... Arlene Sussman, MD, a highly regarded breast imaging and ... explore how telemedicine best practices allow for the access ... virtually anywhere. Click here to register for ... 4, 2015 at 1:00 pm CT. , Hospitals must ...
    (Date:3/3/2015)... Introducing 3D Digital Technologies to their ... leader in Digital Dentistry. Acute precision in ... replicas, leaving no room for error during the ... are able to significantly reduce “chair time” and ... quality while reducing labor and material costs proving ...
    (Date:3/3/2015)... (PRWEB) March 03, 2015 In a ... Morning Edition, science correspondent Shankar Vedantam shared ... Pennsylvania about the drastic decrease in hand-hygiene compliance that occurs ... that the problem could be solved in part by alerts ... hygiene when they enter and exit a patient’s room. ...
    (Date:3/3/2015)... 2015) (PRWEB) March 03, 2015 President/CEO ... innovator in the travel industry for the past 10 ... plan. To fulfill his vision for the future of ... fun, exciting and well-compensated positions as travel sales specialists ... sales center planned for the Boynton Beach, Florida area. ...
    (Date:3/3/2015)... Retrofit , the comprehensive weight management ... today announces the appointment of its new chief technology ... Mary Pigatti has recruited technology, healthcare and people ... the fast-growing company, which was recently named one of ... , “Retrofit is thrilled to announce this new acquisition ...
    Breaking Medicine News(10 mins):Health News:Latest vRad Webinar: Building World-Class Breast Imaging Services Virtually Anywhere with Telemedicine Best Practices 2Health News:Latest vRad Webinar: Building World-Class Breast Imaging Services Virtually Anywhere with Telemedicine Best Practices 3Health News:Latest vRad Webinar: Building World-Class Breast Imaging Services Virtually Anywhere with Telemedicine Best Practices 4Health News:Iverson Dental Labs Introduces 3D Digital Dental Technology for Superior Products 2Health News:Iverson Dental Labs Introduces 3D Digital Dental Technology for Superior Products 3Health News:BIOVIGIL Hygiene Technologies Answers Call for Hand Hygiene Alerts on Badges 2Health News:BIOVIGIL Hygiene Technologies Answers Call for Hand Hygiene Alerts on Badges 3Health News:First Class Vacations, Inc. Expansion Plan Creates 400 Jobs In South Florida 2Health News:First Class Vacations, Inc. Expansion Plan Creates 400 Jobs In South Florida 3Health News:Retrofit Signals Growth: Corporate Weight Management Company Announces Talent Acquisitions 2Health News:Retrofit Signals Growth: Corporate Weight Management Company Announces Talent Acquisitions 3Health News:Retrofit Signals Growth: Corporate Weight Management Company Announces Talent Acquisitions 4
    ... By Steven Reinberg HealthDay Reporter , WEDNESDAY, Sept. ... report released earlier this week, a new study shows that men ... not really need future screening. Conversely, men with a high ... should be monitored and have an increased risk of developing the ...
    ... Adults with congenital heart disease are more likely ... heart-related symptoms and sensations if their parents ... Lephuong Ong from Orion Health Services in Vancouver, ... University in Toronto, Canada, suggest that health care ...
    ... -- Oregon Health & Science University,s Markus Grompe, M.D., ... participate in the prestigious Beta Cell Biology Consortium (BCBC). ... and Kidney Diseases, the consortium,s long-term goal is to ... 1 diabetes patients. "The goal of our work ...
    ... , TUESDAY Sept. 14 (HealthDay News) -- A new antibiotic-resistant ... a handful of people in North America, with three of ... Tuesday. But the bacterium -- designated New Delhi ... bacterium that,s been present in the United States for many ...
    ... well known that exposure to radiation has multiple harmful effects ... been unclear to what extent such exposure increases a person,s ... large-scale study of the relationship between radiation dose and risk ... Nagasaki, Japan reveals a similar risk in the development of ...
    ... Arnhem, 15 September 2010 A recent TNS NIPO survey, on ... Association of Urology (EAU), showed that almost four out of 10 ... from urinary complaints. The same number of men also said in ... cancer. The TNS NIPO survey also indicated that a ...
    Cached Medicine News:Health News:Men With Low PSA at 60 Might Not Need Further Screening 2Health News:Men With Low PSA at 60 Might Not Need Further Screening 3Health News:Overprotective parents may impact heart anxiety in adults with congenital heart conditions 2Health News:OHSU research team joins elite consortium dedicated to curing type 1 diabetes 2Health News:New Drug-Resistant 'Superbug' Reaches U.S. Shores 2Health News:New Drug-Resistant 'Superbug' Reaches U.S. Shores 3Health News:Radiation exposure poses similar risk of first and second cancers in atomic bomb survivors 2
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    Medicine Products: